367-25-9

应用筛选条件

关键词:'367-25-9'

显示 1-5 共 5 条结果关于 "367-25-9" 范围论文

Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up.

Ferdinando Maggioni et al.

The journal of headache and pain, 6(4), 322-324 (2005-12-20)

We conducted a study on 367 patients (86% female, 14% male; mean age 37+/-15 years) suffering from migraine with and without aura and chronic tension-type headache to evaluate the incidence of weight gain, an undesirable side effect observed during prophylactic

Helicobacter pylori Antigen But Not the Organism Is Occasionally Present Within Germinal Centers: Implications for Patient Management and Biology.

Nya D Nelson et al.

The American journal of surgical pathology, 44(11), 1528-1534 (2020-07-14)

Helicobacter pylori infection is present in two thirds of the world's population and induces a myriad of human diseases, ranging from gastritis to gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Detection is critical for treatment and may require immunohistochemical (IHC)

MicroRNA dynamics during human embryonic stem cell differentiation to pancreatic endoderm.

Gary B Fogel et al.

Gene, 574(2), 359-370 (2015-08-25)

MicroRNAs (miRNAs) are small non-coding RNAs that have emerged as critical regulators of human embryonic stem cell (hESC) pluripotency and differentiation. Despite the wealth of information about the role individual that miRNAs play in these two processes, there has yet

Leucine-rich repeat 11 of Toll-like receptor 9 can tightly bind to CpG-containing oligodeoxynucleotides, and the positively charged residues are critical for the high affinity.

Xichun Pan et al.

The Journal of biological chemistry, 287(36), 30596-30609 (2012-07-24)

TLR9 is a receptor for sensing bacterial DNA/CpG-containing oligonucleotides (CpG ODN). The extracellular domain (ECD) of human TLR9 (hTLR9) is composed of 25 leucine-rich repeats (LRR) contributing to the binding of CpG ODN. Herein, we showed that among LRR2, -5

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Filip Janku et al.

PloS one, 6(7), e22769-e22769 (2011-08-11)

Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis. Tumor tissues from 504 patients with diverse cancers referred to

1/1